PaTHway Phase 3 Trial Analysis

TRIAL Albumin-adjusted Serum Calcium (Mean +/- SE) by Visit ратнішач 10.0 9.5 Calcium Corrected for 9.0 Albumin mg/dL Mean (± SE) 19 8.5 8.0 7.5 0 HH HH HH H H 8 HH TransCon PTH -Placebo HH 12 16 20 20 Weeks 24 28 ascendis pharma TransCon PTH patients maintained mean serum calcium levels in the normal range at all study visits TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution.

View entire presentation